Effect of Alternative Aluminum Adjuvants on the Absorption and Immunogenicity of HPV16 L1 VLPs in Mice
暂无分享,去创建一个
Li Shi | R. Sitrin | J. Heinrichs | P. Ahl | Su Wang | M. Caulfield | T. Tobery | J. Cook | Michael J Caulfield | Su Wang | Bei Wang | Timothy W Tobery | Henryck Mach | Patrick L Ahl | Jayme L Cannon | James C Cook | Jon H Heinrichs | Robert D Sitrin | Jayme Cannon | Li Shi | Bei Wang | H. Mach
[1] J. White,et al. Solubilization of aluminum-containing adjuvants by constituents of interstitial fluid. , 1991, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.
[2] F. Regnier,et al. Effect of protein adsorption on the surface charge characteristics of aluminium-containing adjuvants. , 1994, Vaccine.
[3] J. White,et al. Structure and properties of aluminum-containing adjuvants. , 1995, Pharmaceutical biotechnology.
[4] M. Powell,et al. Vaccine Design , 1995, Pharmaceutical Biotechnology.
[5] Julian Peto,et al. Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .
[6] D. Volkin,et al. Ultraviolet absorption spectroscopy. , 1995, Methods in molecular biology.
[7] F. Vogel,et al. A compendium of vaccine adjuvants and excipients. , 1995, Pharmaceutical biotechnology.
[8] V. Moreno,et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. , 1995, Journal of the National Cancer Institute.
[9] M. Rosolowsky,et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. , 1995, Vaccine.
[10] R. Wagner,et al. Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles. , 1996, Virology.
[11] N. Christensen,et al. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus , 1996, Journal of virology.
[12] A. McMichael,et al. Rapid Effector Function in CD8+ Memory T Cells , 1997, The Journal of experimental medicine.
[13] A. Sher,et al. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. , 1997, Journal of immunology.
[14] M. Suckow,et al. In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. , 1997, Vaccine.
[15] K. Jansen,et al. Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae. , 1999, Protein expression and purification.
[16] J. Peto,et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.
[17] N. Muñoz,et al. Human papillomavirus and cancer: the epidemiological evidence. , 2000, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[18] F. Authier,et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. , 2001, Brain : a journal of neurology.
[19] C. Wheeler,et al. A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.
[20] H. HogenEsch,et al. Mechanisms of stimulation of the immune response by aluminum adjuvants. , 2002, Vaccine.
[21] W. Mcclements,et al. Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques. , 2003, Vaccine.
[22] Xu Liu,et al. Adjuvant synergy in the response to hepatitis B vaccines. , 2003, Vaccine.
[23] E. B. Lindblad. Aluminium adjuvants--in retrospect and prospect. , 2004, Vaccine.
[24] Daron G Ferris,et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.
[25] S. Hem,et al. Aluminum Compounds Used as Adjuvants in Vaccines , 1990, Pharmaceutical Research.
[26] M. Caulfield,et al. Identification of T-cell epitopes using ELISpot and peptide pool arrays. , 2004, Methods in molecular medicine.
[27] C. Wheeler,et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized, controlled trial , 2005 .
[28] W. Mcclements,et al. Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant , 2005, Journal of immune based therapies and vaccines.
[29] C. Wheeler,et al. Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial , 2006, Obstetrics and gynecology.
[30] K. Jansen,et al. Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). , 2006, Journal of pharmaceutical sciences.
[31] J. Brewer. (How) do aluminium adjuvants work? , 2006, Immunology letters.
[32] Brigitte Colau,et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. , 2006, Vaccine.
[33] G. Krogh,et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.
[34] F. Bray,et al. Chapter 2: The burden of HPV-related cancers. , 2006, Vaccine.
[35] M. Kosinski,et al. GARDASIL®: Prophylactic Human Papillomavirus Vaccine Development – From Bench Top to Bed‐side , 2007, Clinical pharmacology and therapeutics.